Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Merimepodib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ViralClear Partners with AMRI on the Manufacture of Merimepodib API
    ViralClear Partners with AMRI on the Manufacture of Merimepodib API

    08 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2020/07/08/2059504/22558/en/ViralClear-Pharmaceuticals-partners-with-Albany-Molecular-Research-Inc-on-the-manufacture-of-merimepodib-active-pharmaceutical-ingredient-development-for-the-potential-treatment-of.html

    GLOBENEWSWIRE
    08 Jul 2020
    Share Share
    FDA Clears the invg NDA to Enable the PhII Trial of ViralClear’s Merimepodib
    FDA Clears the invg NDA to Enable the PhII Trial of ViralClear’s Merimepodib

    18 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/18/2034956/0/en/FDA-Clears-the-Investigational-New-Drug-Application-to-Enable-the-Phase-II-Trial-of-ViralClear-s-Merimepodib-Oral-Solution-to-Treat-Adult-Patients-with-Advanced-COVID-19-to-Proceed.html

    GLOBENEWSWIRE
    18 May 2020
    Share Share
    ViralClear Publishes in F1000 Research In Vitro Data Synergy between Merimepodib
    ViralClear Publishes in F1000 Research In Vitro Data Synergy between Merimepodib

    14 May 2020

    // PRESS RELEASE

    https://ir.biosig.com/press-releases/detail/199/viralclear-publishes-in-f1000-research-in-vitro-data

    PRESS RELEASE
    14 May 2020
    Share Share
    ViralClear Submits In Vitro Data Merimepodib and Remdesivir Synergistic Activity
    ViralClear Submits In Vitro Data Merimepodib and Remdesivir Synergistic Activity

    30 Apr 2020

    // BUSINESSINSIDER

    https://markets.businessinsider.com/news/stocks/viralclear-submits-in-vitro-data-on-merimepodib-and-remdesivir-synergistic-activity-against-the-covid-19-novel-coronavirus-to-a-peer-reviewed-journal-1029150595

    BUSINESSINSIDER
    30 Apr 2020
    Share Share
    ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir
    ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir

    23 Apr 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/04/23/2021020/0/en/ViralClear-Publishes-Comparative-In-Vitro-Data-on-Merimepodib-and-Remdesivir-Activity-Against-the-COVID-19-Novel-Coronavirus-in-F1000-Research.html

    GLOBENEWSWIRE
    23 Apr 2020
    Share Share